Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Piet Maes and Cyril Barbezange.
Piet Maes
Connection Strength
0.236
Cyril Barbezange
  1. Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. Eur Respir J. 2022 02; 59(2).
    View in: PubMed
    Score: 0.062
  2. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. Euro Surveill. 2021 07; 26(27).
    View in: PubMed
    Score: 0.060
  3. Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials. 2020 Dec 14; 21(1):1024.
    View in: PubMed
    Score: 0.057
  4. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials. 2020 Nov 27; 21(1):981.
    View in: PubMed
    Score: 0.057
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.